Statins for primary prevention in adults aged 30–50 years with moderate cardiovascular risk: quantitative benefit, harms, and evidence gaps

Next Research · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles